Amylyx Pharmaceuticals EMEA

Company snapshot

Amylyx Pharmaceuticals, Inc is a [biopharmaceutical](en.wikipedia.org/wiki/Biopharmaceutical) company headquartered in [Cambridge, Massachusetts](en.wikipedia.org/wiki/Cambridge,_Massach). Amylyx is best known for [AMX0035](en.wikipedia.org/wiki/Sodium_phenylbutyr), an experimental therapy for [amyotrophic lateral sclerosis](en.wikipedia.org/wiki/Amyotrophic_latera). AMX0035 was approved for medic

• 7 active pipeline program(s) linked via ClinicalTrials.gov.
• 9 US patent(s) indexed to this assignee profile.
• 7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Amylyx Pharmaceuticals EMEA. Not investment advice.

• Peer + 0 momentum

  Denali Therapeutics

  TA overlap score 24.6

• Peer + 0 momentum

  NeuroSense Therapeutics

  TA overlap score 21.2

Recent activity

Latest pipeline, patent, and corporate events for Amylyx Pharmaceuticals EMEA.

1. Jun 8, 2026 Clinical update

   AMX0114 — Phase 1

2. Jun 8, 2026 Clinical update

   AMX0035 — Phase 2

3. Jun 5, 2026 Clinical update

   AMX0035 — Phase 2

4. May 23, 2026 Clinical update

   AMX0035 — Phase 3

5. May 23, 2026 Clinical update

   AMX0035 — Phase 3

View all clinical trial activity →

• What is Amylyx Pharmaceuticals EMEA?

  Amylyx Pharmaceuticals EMEA is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker AMLX. Primary therapeutic focus areas include Alzheimer Disease, Amyotrophic Lateral Sclerosis, Progressive Supranuclear Palsy, Wolfram Syndrome, Post Bariatric Hy

• Is Amylyx Pharmaceuticals EMEA publicly traded?

  Yes. Amylyx Pharmaceuticals EMEA is listed with ticker AMLX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Amylyx Pharmaceuticals EMEA develop or market?

  We link 2 drug profile(s) where Amylyx Pharmaceuticals EMEA is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/amylyx-pharmaceuticals#company-drugs.

• What are the latest developments for Amylyx Pharmaceuticals EMEA?

  In the last 12 months our linked public records show 7 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Amylyx Pharmaceuticals EMEA focus on?

  Amylyx Pharmaceuticals EMEA focuses on Alzheimer Disease, Amyotrophic Lateral Sclerosis, Progressive Supranuclear Palsy based on our analysis of their pipeline programs and drug development activities.